Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab-Ipilimumab With cfDNA-guided Treatment Intensification in Metastatic NSCLC
NCT04966676Phase 2Terminated
- Sponsor
- University Health Network
- Start
- Jan 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC), sponsored by University Health Network. Primary endpoint: Progression-Free Survival Rate at 6 months. Started Jan 2022; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04966676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966676.